Ronald W. Stam

Dr. Ronald W. Stam


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
JBJudith M. Boer
Judith M. Boer
MVMaria Grazia Valsecchi
Maria Grazia Valsecchi
FHFemke M. Hormann
Femke M. Hormann
ŽAŽeljko Antić
Željko Antić
MZMarketa Zaliova
Marketa Zaliova
RPRob Pieters
Rob Pieters

1 February 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
MKMark Kerstjens
Mark Kerstjens
SPSandra S. Pinhancos
Sandra S. Pinhancos
PCPatricia Garrido Castro
Patricia Garrido Castro
PSPauline Schneider
Pauline Schneider
PWPriscilla Wander
Priscilla Wander
RSRonald W. Stam
Ronald W. Stam

1 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JTJuan Ramón Tejedor
Juan Ramón Tejedor
CBClara Bueno
Clara Bueno
MVMeritxell Vinyoles
Meritxell Vinyoles
PPPaolo Petazzi
Paolo Petazzi
AAAntonio Agraz-Doblas
Antonio Agraz-Doblas
PMPablo Menendez
Pablo Menendez
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. As predicted by its prenatal origin, infant B-ALL (iB-ALL) shows an exceptionally silent DNA mutational landscape, suggesting that alternative epigenetic mechanisms may substantially contribute to its leukemogenesis. Here, we have integrated genome-wide DNA methylome and transcriptome data from 69 patients with de novo MLL-rearranged leukemia (MLLr) and non-MLLr iB-ALL leukemia uniformly treated according to the Interfant-99/06 protocol. iB-ALL methylome signatures display a plethora of common and specific alterations associated with chromatin states related to enhancer and transcriptional control in normal hematopoietic cells. DNA methylation, gene expression, and gene coexpression network analyses segregated MLLr away from non-MLLr iB-ALL and identified a coordinated and enriched expression of the AP-1 complex members FOS and JUN and RUNX factors in MLLr iB-ALL, consistent with the significant enrichment of hypomethylated CpGs in these genes. Integrative methylome-transcriptome analysis identified consistent cancer cell vulnerabilities, revealed a robust iB-ALL–specific gene expression–correlating dmCpG signature, and confirmed an epigenetic control of AP-1 and RUNX members in reshaping the molecular network of MLLr iB-ALL. Finally, pharmacological inhibition or functional ablation of AP-1 dramatically impaired MLLr-leukemic growth in vitro and in vivo using MLLr-iB-ALL patient–derived xenografts, providing rationale for new therapeutic avenues in MLLr-iB-ALL.

24 July 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
TCTito Candelli
Tito Candelli
PSPauline Schneider
Pauline Schneider
PCPatricia Garrido Castro
Patricia Garrido Castro
LJLuke A. Jones
Luke A. Jones
EBEduard Bodewes
Eduard Bodewes
RSRonald W. Stam
Ronald W. Stam
Infants with MLL-rearranged infant acute lymphoblastic leukemia (MLL-r iALL) undergo intense therapy to counter a highly aggressive malignancy with survival rates of only 30–40%. The majority of patients initially show therapy response, but in two-thirds of cases the leukemia returns, typically during treatment. The glucocorticoid drug prednisone is established as a major player in the treatment of leukemia and the in vivo response to prednisone monotreatment is currently the best indicator of risk for MLL-r iALL. We used two different single-cell RNA sequencing technologies to analyze the expression of a prednisone-dependent signature, derived from an independent study, in diagnostic bone marrow and peripheral blood biopsies. This allowed us to classify individual leukemic cells as either resistant or sensitive to treatment and show that quantification of these two groups can be used to better predict the occurrence of future relapse in individual patients. This work also sheds light on the nature of the therapy-resistant subpopulation of relapse-initiating cells. Leukemic cells associated with high relapse risk are characterized by basal activation of glucocorticoid response, smaller size, and a quiescent gene expression program with cell stemness properties. These results improve current risk stratification and elucidate leukemic therapy-resistant subpopulations at diagnosis.

Verified
Journal Article
Open access
PDF file
FAFabienne R. S. Adriaanse
Fabienne R. S. Adriaanse
PSPauline Schneider
Pauline Schneider
SASusan T. C. J. M. Arentsen-Peters
Susan T. C. J. M. Arentsen-Peters
AFAna M. Neves da Fonseca
Ana M. Neves da Fonseca
JSJanine Stutterheim
Janine Stutterheim
RSRonald W. Stam
Ronald W. Stam
Pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) exhibit favorable survival rates. However, for AML and ALL patients carrying KMT2A gene translocations clinical outcome remains unsatisfactory. Key players in KMT2A-fusion-driven leukemogenesis include menin and DOT1L. Recently, menin inhibitors like revumenib have garnered attention for their potential therapeutic efficacy in treating KMT2A-rearranged acute leukemias. However, resistance to menin inhibition poses challenges, and identifying which patients would benefit from revumenib treatment is crucial. Here, we investigated the in vitro response to revumenib in KMT2A-rearranged ALL and AML. While ALL samples show rapid, dose-dependent induction of leukemic cell death, AML responses are much slower and promote myeloid differentiation. Furthermore, we reveal that acquired resistance to revumenib in KMT2A-rearranged ALL cells can occur either through the acquisition of MEN1 mutations or independently of mutations in MEN1. Finally, we demonstrate significant synergy between revumenib and the DOT1L inhibitor pinometostat in KMT2A-rearranged ALL, suggesting that such drug combinations represent a potent therapeutic strategy for these patients. Collectively, our findings underscore the complexity of resistance mechanisms and advocate for precise patient stratification to optimize the use of menin inhibitors in KMT2A-rearranged acute leukemia.

29 May 2025 in Blood
Verified
Journal Article
Open access
AFAïda Falgàs
Aïda Falgàs
RLRodrigo Lázaro-Gorines
Rodrigo Lázaro-Gorines
SZSamanta Romina Zanetti
Samanta Romina Zanetti
LRLaura Rubio-Pérez
Laura Rubio-Pérez
AMAlba Martínez-Moreno
Alba Martínez-Moreno
PMPablo Menéndez
Pablo Menéndez
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19) T-cell therapy, >50% of patients relapse within a year. Both leukemia cell–intrinsic factors favoring immune escape and poor CAR T-cell persistence contribute to clinical failure. Moreover, the expression of immune checkpoint receptors (ICRs) and their ligands within the bone marrow (BM) microenvironment may contribute to leukemia progression and therapy resistance. Here, we characterized the expression of ICRs and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells (MSCs) from B-ALL BM samples at diagnosis and relapse, comparing them with age-matched healthy BM controls. Our findings reveal a significantly upregulated expression of TIM-3 in T cells and its ligand, galectin-9, in both blasts and MSCs throughout disease progression. The expression of galectin-9 in B-ALL blasts and TIM-3 in CAR19 T cells negatively correlates with clinical outcome. Furthermore, we demonstrate that galectin-9 impairs CAR19 T-cell homeostasis and cytotoxicity. Notably, an engineered TIM-3–Fc decoy receptor, delivered either by primary T cells coadministered with CAR19 T cells or via a bicistronic all-in-one CAR19–TIM-3–Fc construct, improved the antileukemia efficacy and persistence of CAR19 T cells in B-ALL xenograft models. Mechanistically, CAR19–TIM-3–Fc T-cell treatment promotes the in vivo expansion of transduced and bystander effector and memory T cells, as determined by spectral flow cytometry. Collectively, these TIM-3–Fc decoy–armored CAR19 T cells offer a promising therapeutic strategy for patients with R/R B-ALL.